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Introduction 
 The steps through which cardiac differentiation progresses are fairly well 
defined, but some mechanistic questions still remain.  It is well established that 
Oct4 is a key regulator of pluripotency.  Emerging data supports claims that Oct4 
may have an active role in cardiac lineage commitment.  To further explore this 
possibility, in vitro development modeled through embryoid bodies may provide a 
platform to confirm the role of Oct4 in a setting reflective of normal cardiac 
differentiation.  
 
Pluripotent Cells 
 
 Embryonic stem (ES) cells are pluripotent cells capable of differentiating 
into all somatic cell types, and serve as an effective in vitro model of 
development for many mammalian systems (Evans, 2005).   The groundwork for 
ES cell work was laid by pluripotent cells isolated from teratocarcinomas of mice, 
referred to as embryonal carcinoma (EC) cells (Damjanov, 2005; Andrews et al., 
2005, Chambers and Smith, 2004).  EC cells were isolated from testicular 
teratocarcinomas, and were observed to differentiate successfully into all three 
germ layers upon injection into immune-compromised mice (Andrews et al., 
2005; Damjanov, 2005).  When isolated and injected into a mouse blastocyst, the 
EC cells contributed to a variety of cell types in the resulting mice (Chambers & 
Smith, 2004).  When cultured in suspension, EC cells formed aggregates 
resembling mouse egg-cylinder stage embryos, in both morphology and 
differentiation capacity (Stevens, 1960).   
 Based on the knowledge from EC cells, in 1981, Martin, as well as Evans 
and Kaufman, both successfully isolated and cultured mouse ES (mES) cells 
from the inner cell mass (ICM) of normal mouse blastocysts for the first time 
(Martin, 1981; Evans and Kaufman, 1981).  In contrast to EC cells, ES cells are 
not malignant and can regularly contribute to the germline of chimeric animals 
(Andrews et al., 2005; Bradley et al., 1984).  They maintain pluripotency and can 
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be cultured indefinitely when grown on a fibroblast feeder layer in the presence of 
serum and leukemia inhibitory factor (LIF) (Evans, 2005; Ying et al., 2008;  Smith 
et al., 1988).  Early studies indicated that medium conditioned with buffalo rat 
liver cells could replace a feeder layer of fibroblasts with the purpose of 
maintaining ES cells in a pluripotent state (Smith and Hooper, 1987).  LIF, a 
member of the interleukin-6 cytokine family, was determined to be the active 
molecule in the aforementioned medium that functioned to maintain the 
pluripotency of ES cells (Smith et al., 1988).  Upon removal of LIF from culture 
conditions, ES cells begin to spontaneously differentiate (Chambers and Smith, 
2004).   
 After further analysis of LIF and the mechanism by which it maintains ES 
cells in an undifferentiated state, it was determined that it functioned to activate 
specific genes which in turn activate or repress other transcription factors that 
prevent a cell from differentiating and allow for self-renewal to maintain 
pluripotency (Chambers and Smith, 2004).  After it was determined that LIF 
played an active role in activating these “pluripotent” gene networks, a closer 
examination revealed three genes in particular that are central to pluripotency:  
Sox2 (Masui et al., 2007), Nanog (Chambers et al., 2003), and Oct4, which is 
also known as Pou5f1 (Niwa et al., 2000).  All three of these genes are 
expressed in the inner cell mass (ICM) of blastocysts, epiblast cells, and ES cells 
(Chambers and Smith, 2004).  Oct4 has been demonstrated to be critical for the 
maintenance of pluripotency of ICM and ES cells (Kehler et al., 2004; Zeineddine 
et al., 2006).   
 Pluripotent cells have become increasingly more attractive for possible 
clinical research and treatments, including drug development, cell therapy, and in 
vitro developmental studies.  However, the ethical implications associated with 
destroying a human blastocyst to harvest cells of the ICM for ES culture is not 
likely an obstacle that will be overcome for use in clinical settings (Evans, 2005; 
Moerkamp and Goumans, 2012).  In 2006, Takahashi and Yamanaka determined 
a way to dedifferentiate somatic cell types into a pluripotent state.  Murine 
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fibroblasts were transfected using retroviral vectors encoding Oct4, Sox2, Klf4, 
and c-Myc (Takahashi and Yamanaka, 2006).  The cells that were successfully 
transfected began to express genes that are specific to pluripotent cells; they 
also displayed ES-like morphology and growth patterns (Takahashi and 
Yamanaka, 2006). These reprogrammed cells were termed “induced pluripotent 
stem cells,” or iPS cells (Takahashi and Yamanaka, 2006).  High endogenous 
expression of Oct4, Sox2, and Nanog was observed in these iPS cells 
(Takahaski and Yamanaka, 2006; Wernig et al., 2007).  Further studies to 
characterize these cells by the Wernig group in 2007 confirmed that the DNA 
methylation state and chromatin state of iPS cells were nearly analogous to ES 
cells (Wernig et al., 2007).  However, recent studies suggest that early passages 
of iPS cells maintain some degree of epigenetic memory from the original 
somatic cell type (Ohi et al., 2011; Kim et al., 2010; Moerkamp et al., 2012).  For 
example, the DNA methylation statuses of some genes were similar to the cell 
type of origin, such as hepatocytes, skin fibroblasts, and melanocytes (Ohi et al., 
2011; Kim et al., 2010; Moerkamp et al., 2012).  The epigenetic memory was not 
observed in the iPS cells after subsequent passaging, suggesting that they do 
eventually reach a more ES-like state (Ohi et al., 2011).  iPS cells are analogous 
to ES cells in that they are pluripotent and have the capacity to generate chimeric 
mice when introduced to a normal mouse blastocyst (Takahashi and Yamanaka, 
2006; Wernig et al., 2007).  Both human ES (Thompson et al., 1998) and iPS 
(Rust et al., 2006; Yu et al., 2007) have been successfully isolated and cultured.  
The significance of both ES and iPS cells can be found in their unique ability to 
differentiate into any somatic cell of the body.  To date, there is not a population 
capable of such plasticity that exists in the adult mammal.  Through the close 
examination of differentiation of these pluripotent cells in vitro, molecular 
interactions during development may be better understood.   
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In Vitro Differentiation Methods 
 
In early studies, cells from teratocarcinomas of testis were isolated for 
further characterization (Stevens, 1960; Pierce and Dixon, 1959).  When injected 
intraperitoneally, the cells were observed to form aggregates, termed as 
embryoid bodies (EBs) (Pierce and Dixon, 1959).  The EBs contained tissue 
types from all three germ layers (Pierce and Dixon, 1959; Stevens, 1960).  When 
EBs were transplanted into the ocular cavity of mice, all three germ layers were 
also found in the differentiated cells (Stevens, 1960).  A subset of pluripotent 
cells existed in the transplanted EBs with the capability of populating entirely new 
tumors when subsequently transplanted (Stevens, 1960).  Further studies 
indicated that the EBs formed in vitro as well as in vivo were comparable to 
normal mouse embryos in morphology, differentiation capacity, and patterning 
(Stevens, 1960; Pierce and Dixon, 1959; Pierce and Verney, 1961).  A 
homogenous pluripotent stem cell population was isolated from mouse 
teratocarcinomas and cultured in vitro by Martin and Evans in 1974.  The cells 
comprising the population were termed embryonal carcinoma (EC) cells (Martin 
and Evans, 1974).  When aggregated and allowed to differentiate in vitro, cystic 
EBs demonstrated a patterning of differentiation similar to that of ICM cells 
cultured in vitro (Martin et al., 1977). 
Following the successful isolation and culture of mouse ES cells and 
revelation of iPS cells, it was demonstrated that both have the capacity to 
aggregate into EB structures (Doetschman, 1985; Keller, 1995; Takahashi, 2006; 
Wernig, 2007).  In the study done by Doetschman in 1985, it was determined that 
mouse ES (mES) cells in an EB formation are most similar to normal mouse 
embryos between days 6 and 8 in the egg cylinder stage.  EBs formed using 
mES cells bear a stronger resemblance of a normal mouse embryo than EBs 
formed with EC cells in that they develop a normal mesoderm layer between the 
endoderm and ectoderm layers (Doetschman, 1985).  This indicates that mES 
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EBs resemble the morphology and differentiation capacity of normal mouse 
embryos, which makes them good models for in vitro developmental studies.   
 Dependent on the study and desired ending cell type, a wide variety of 
methods have been proposed to differentiate ES cells toward specific lineages.  
Typically, one of the following culture conditions are used to differentiate ES cells: 
embryoid body (EB) formation, monolayer culture on extracellular matrix (ECM) 
proteins, or co-culture with a specific somatic cell type (Murry and Keller, 2008).  
Cells may be allowed to differentiate spontaneously, or may be directed toward a 
particular lineage by manipulation of the extracellular environment (i.e. soluble 
factors, small molecules).  EB models have been demonstrated to best 
recapitulate the developing embryo, and are the most common method of 
differentiation (Doetschman, 1985; Keller, 1995) 
 For the purpose of this study, EBs made from iPS cells were chosen as 
the means of differentiation.  EBs can be formed with various methods, such as 
static suspension in low-adherence plates, hydrodynamic culture, centrifugation, 
and hanging drop.  Each method offers different strengths, as well as limitations.  
Static culture of EBs is arguably the simplest method by which to form EBs.  A 
given number of single ES cells are suspended in medium on a low-adherence 
plate, to which the cells are unlikely to form attachments with the surface (Bratt-
Leal et al., 2009).  The cells will spontaneously form cell-cell adhesions, resulting 
in EBs.  However, there is no way to control how many cells aggregate in this 
method, and the resulting population of EBs is heterogeneous in size and shape 
(Bratt-Leal et al., 2009; Kurosawa, 2007).  In hydrodynamic culture, single ES 
cells are again suspended in medium on a low-adherence surface.  In contrast to 
the static method, the culture is constantly moving.  This method can be utilized 
with techniques using rotary orbital culture, stirred flasks, or spinner flasks (Bratt-
Leal et al., 2009).  The resultant EBs are more homogeneous than static cultures, 
but exact sizes cannot be controlled.  The culture conditions are also maintained 
at a higher level of uniformity, as the medium is continuously moving, distributing 
oxygen, nutrients, and soluble factors evenly (Kurosawa, 2007; Bratt-Leal et al., 
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2009).  The centrifugation, or spin, method allow for selection of the size of EB 
desired.  A defined number of cells is suspended in medium and dispersed into 
the wells of a low-adherence plate.  The plate is centrifuged, forcing the cells to 
aggregate in the center of the wells (Antonchuk, 2013).  EBs resulting from this 
method are generally uniform in size and shape, but tend to exhibit some signs of 
cell death near the center of the EB (Antonchuk, 2013).  The observed cell death 
may be attributed to the force exerted on the cells during centrifugation.  When 
EBs are formed via the hanging drop method, a designated number of cells are 
suspended from the lid of petri culture dish in drops of media (Bratt-Leal et al., 
2009; Kurosawa, 2007).  The rounded drops facilitate the formation of EBs 
through gravitational pull, allowing them to aggregate.  EBs generated via 
hanging drop method are generally homogenous, in size and shape (Keller, 
1995; Bratt-Leal et al., 2009).  It has been observed that EBs formed with this 
method develop polarity (Mogi, 2009; ten Berge et al., 2008).  In order to 
decrease variability within individual cultures and improve reproducibility between 
biological replicates, the hanging drop method was chosen as the differentiation 
method in this work.  By choosing to allow spontaneous differentiation versus 
introducing soluble factors to direct the differentiation, the EBs will be a more 
accurate recapitulation of temporal events of cardiogenesis in the developing 
embryo.  Previous publications have demonstrated from in vitro studies that 
pluripotent cell populations can generate cells in all stages of cardiac 
commitment, from early precursors to specialized, mature cells (Maltsev et al., 
1994; Moerkamp and Goumans, 2012).  
 
Cardiac Lineage Commitment and Oct4 Involvement 
 
The heart is the first functional organ to develop in an embryo (Van Vliet et 
al., 2012; Rana et al., 2013).  The cells of the ICM of the blastocyst express 
pluripotency-regulatory genes such as Oct4, Sox2, and Nanog (Figure 1) 
(Stefanovic et al., 2009).  Oct4 itself has been determined to be required for 
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pluripotency maintenance (Nichols et al., 1998; Niwa, 2007; Kehler et al., 2004).  
Knockout models cannot maintain a pluripotent state in the ICM after blastocyst 
development (Nichols et al., 1998), and repression of Oct4 in vitro results in a 
loss of pluripotency and dedifferentiation to trophectoderm (Niwa et al., 2000).    
Oct4 expression is generally limited to oocytes, ES cells, and primordial germ 
cells (Scholer et al., 1989; Yeom et al., 1996).  By day 8.0-8.5, the only cells still 
expressing Oct4 are the primordial germ cells (Scholer et al., 1990).   
Pluripotent cells have been demonstrated to be sensitive to the level of 
Oct4 expression.  A certain level will maintain a pluripotent phenotype, while 
upregulation pushes a cell toward primitive endoderm or mesoderm (Niwa et al., 
2000).  Sox2 and Oct4 have been demonstrated to coregulate certain genes 
tightly regulating pluripotency via binding motifs in the same enhancer regions 
(Figure 1A) (Wamstead et al., 2012; Stefanovic et al., 2009; Masui et al., 2007).  
When Oct4 is expressed at a basal level, it forms a complex with Sox2 binding to 
the enhancer and/or promoter region of many genes to maintain the pluripotent 
state of the cell (Stefanovic et al. 2009).  Together, they tightly regulate the 
expression of genes directly involved in maintenance of pluripotencty, such as 
Oct4, Sox2, and Nanog (Masui et al., 2007, Bernstein et al., 2006).  In Sox2-null 
mice, Oct4 forced expression can rescue pluripotency if present at the proper 
level (Masui et al., 2007).   
In the developing embryo, Oct4 is upregulated during gastrulation, a 
process undergone by the primitive streak (Buckingham et al., 2005).  
Gastrulation is the process by which the three germ layers develop (Buckingham 
et al., 2005, Van Vliet et al., 2012).  An increase in Oct4 expression leads to 
stimulates Sox17 expression (Figure 1) (Van Vliet et al., 2012; Stefanovic et al., 
2009).  Sox17 competes with Sox2 to form complexes with Oct4 (Stefanovic et 
al., 2009).  The Oct4-Sox17 complex binds to DNA upstream of Sox17, 
stimulating its transcription (Stefanovic et al., 2009).  With Oct4 binding Sox17 
instead of Sox2, there is no complex binding to the Sox2 promoter so it is no 
longer expressed.  Sox17 is a transcription factor with expression observed in 
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endoderm and some mesoderm.  Inhibition of Sox17 does not prevent mesoderm 
formation, but it does prevent induction of mesoderm posterior 1 (Mesp1), 
suggesting that it may directly regulate expression of this gene (Van Vliet et al., 
2012; Liu et al., 2007).  Differential Oct4 expression may therefore influence 
Sox17 expression, which in turn regulates the expression of Mesp1, providing a 
direct link between Oct4 expression at gastrulation and the control of genes 
involved in early cardiac commitment. 
The cardiac mesoderm of mice originates from the anterior part of the 
primitive streak of the embryo, which Mesp1 facilitates (Vincent and Buckingham, 
2010).  Mesp1 expression is one of the first detectable markers of cardiac 
commitment, and a master regulator of cardiac fate determination (Vincent and 
Buckingham, 2010, Van Vliet et al., 2012).    
Figure 1. Cardiac Differentiation. A. Sox2/Sox17-Oct4 loop (adapted from Stefanovic et al., 
2009). B. Gene expression through cell stages along cardiac lineage commitment. (Van Vliet et 
al., 2012; Stefanovic et al., 2009; Rana et al., 2013; Bondue et al., 2011) 
 
Mesp1 functions to downregulate pluripotency genes, and upregulate the 
expression of cardiac transcription factors (Rana et al., 2013).  Mesp1 has been 
demonstrated to directly regulate genes important in cardiac lineage 
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determination such as Nkx2.5, Tbx5, cardiac troponin-T (cTnT), myosin heavy 
chain-6 (Myh6), and myosin light chain-2 (Myl2) (Bondue et al., 2011).  Mesp1 
also has a binding site in the upstream enhancer region of Sox17, leading to 
suppression of the expression of the gene (Bondue et al., 2008).  Multiple binding 
regions for Mesp1 were identified in the promoter of Nkx2.5 specifically (Bondue 
et al., 2008).  Brachyury (Bry) is also required for mesoderm specification and 
expressed during gastrulation into early organogenesis (Figure 1) (Lui et al., 
2007; Leahy et al., 1999).  From the precardiac mesoderm expressing Mesp1 
and Bry, myocardial progenitors capable of differentiating into cardiomyocytes 
(CM), smooth muscle cells (SMC), and endothelial cells arise (Bondue et al., 
2008; Bondue et al., 2011).  These myocardial progenitors express low levels of 
fetal liver kinase-1 (Flk1), which is a receptor for vascular endothelial growth 
factor (VEGF) (Figure 1) (Murry and Keller, 2008), as well as expression of 
platelet-derived growth factor receptor-alpha (PDGFRa) (Bondue et al., 2011), 
both influential factors involved in proliferation and differentiation.  Islet1 (Isl1) 
cooperates with Mesp1 to direct cell fate toward the cardiovascular lineage 
(Bondue et al., 2011).  Isl1 is also expressed in a subset of myocardial progenitor 
cells (Bondue et al., 2011).  
In the developing heart, there are four main contributors: primary heart 
field (PHF), secondary heart field (SHF), cardiac neural crest (CNC), and the 
proepicardial organ (Vincent and Buckingham, 2010).  The cells of the PHF 
contributes to the inflow tract, atria, and left ventricle; cells from the SHF form the 
outflow tract and right ventricle (Abu-Issa and Kirby, 2007; Vincent and 
Buckingham, 2010).  Distinct gene expression patterns have been identified in 
cells of the PHF and SHF (Figure 1).  The cells originating from the PHF express 
Nkx2.5 and Tbx5 (Van Vliet et al., 2012; Rana et al., 2013).  The transcription 
factor Nkx2.5 was determined to be critical for the developing heart tube and 
chambers (Rana et al., 2013).  Tbx5 is also a transcription factor, and it functions 
to regulate many other genes involved in cardiac specification (Rana et al., 2013; 
Vincent and Buckingham, 2010).  It is predominantly expressed in inflow tract, 
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precardiac venous mesoderm, atrio-ventricular canal, and embryonic 
myocardium (Rana et al., 2013).  Cells of the SHF can be identified by 
expression of Isl1 and Tbx1 (Murry and Keller, 2008; Van Vliet et al., 2012; 
Buckingham et al., 2005).   Tbx1 expression directly represses expression of 
Tbx5 (Rana et al., 2013).  It has also been linked to indirect regulation Wnt5a, the 
implications of which will be discussed below (Rana et al., 2013).  Isl1 expression 
is observed primarily in venous and arterial poles of the cardiac tube 
(Buckingham et al., 2005).   
Terminally differentiated cardiomyocytes express the structural genes 
myosin light chain-2 (Myl-2), myosin heavy chain-6 (Myh6), cardiac troponin-T 
(cTnT), and troponin-I (Tnni) (Figure 1) (Miller-Hance et al., 1993; Murry and 
Keller, 2008; Liu et al., 2007).  In the mature cell type, the myosin proteins play a 
large role in muscle contraction, which is a necessary function of cardiomyocytes 
(Wei and Jin, 2011).  Troponin functions to allow crossbridge formation between 
actin and myosin (Wei and Jin, 2011).  Mature cardiomyocytes must express 
these genes in order to generate the required proteins to successfully function.   
Mesodermal differentiation is also influenced by the Wnt and beta-catenin 
pathway (Van Vliet et al., 2012).  Wnt signaling facilitates the mechanism by 
which EBs become polarized (ten Berge et al., 2008).  The canonical Wnt-
signaling pathway has been linked to cardiac lineage commitment (Li et al., 
2013).  In the canonical Wnt pathway, the binding of the Wnt ligand to a receptor 
complex triggers a cascade of intracellular events leading to beta-catenin 
translocation to the nucleus (Rana et al., 2013).  Beta-catenin binds TCF/LEF 
transcription factors and together regulates expression of specific genes (Rana et 
al., 2013).  Residual Oct4 expression after gastrulation coincides with a burst of 
Wnt signaling in the embryo (Lie et al., 2013).  Recent evidence has 
demonstrated a composite binding site for Lef1 and Oct4 in the promoter of 
Mesp1, inducing the expression of Mesp1 (Li et al., 2013).  The joint regulation of 
Mesp1 by both Oct4 and Lef1 provides a novel explanation of the role of Oct4 in 
cardiac fate determination.  With Oct4 directly influencing the expression of 
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Mesp1, investigating the temporal expression of Oct4 in conjunction with 
expression of cardiac-specific genes may help to further characterize the role of 
Oct4 in cardiac lineage commitment. 
 
Oct4 Reporter Cell Line (3F10) 
 
 In order to investigate the proposed interactions of Oct4 in determining 
commitment to the cardiac lineage, an iPS cell line with a reporter sensitive to 
Oct4 expression was utilized.  The cell line was generated via reprogramming of 
fibroblasts from transgenic mice (Greder et al., 2012).  First, pluripotent cells 
were genetically engineered in vitro via a knock-in construct which contains a 
sequence for a Cre-recombinase fused to a tamoxifen-activated estrogen 
receptor in the 3’ untranslated region of the endogenous Oct4 gene (Figure 3) 
(Greder et al., 2012).  The sequence encoding Oct4 is separated from the Cre 
sequence by an internal ribosomal entry site (IRES), allowing for a polycistronic 
transcript (Greder et al., 2012).  Next, cells which had successfully recombined 
and expressed the transgene were used to engineer transgenic mice via 
blastocyst injection.  Transgenic mice expressing the Oct4-MerCreMer transgene 
were then crossed to a double reporter transgenic mouse (Muzumdar et al., 
2007).  The double reporter expressed floxed membrane-targeted tdTomato 
fluorescent protein followed by a poly-adenylation sequence, upstream of 
membrane-targeted enhanced green fluorescent protein (eGFP) under the 
control of a chicken actin promoter from the Rosa26 locus (Figure 3) (Muzumdar 
et al., 2007).  In this double reporter system, prior to Cre-mediated 
recombination, ubiquitous expression of tdTomato will be observed in all cells; 
activated Cre recombinase would cause the excision of tdTomato, and 
subsequent expression of eGFP (Muzumdar et al., 2007).  In generation of a 
double transgenic mouse, cells expressing Oct4 during the period of time that 
tamoxifen is present to activate the Cre recombinase, will be permanently labeled 
with eGFP (Sajini et al., 2012; Greder et al., 2012).  This system is quite sensitive 
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to levels of Oct4 transcripts, allowing for visual identification of cells expressing 
even low levels of Oct4 (Sajini et al., 2012, Greder et al., 2012).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Reporter Construct. Construct of Oct4-mTmG system (adapted from Greder et al., 
2012). Cell membranes constitutively fluoresce with tdTomato until excision by activated Cre 
recombinase (expressed with endogenous Oct4) in the presence of tamoxifen.   
  
From the double transgenic mice, an iPS cell line was generated by 
conventional methods to allow for in vitro developmental studies of Oct4 lineage 
tracing  (Greder et al., 2012; Takahashi and Yamanaka, 2006).  This cell line was 
previously used to describe the Oct4 expression patterns in EBs (Sajini et al., 
2012).  In 2012, Sajini et al. described the timing of specific developmental gene 
expression in an EB model, confirming that EBs do in fact recapitulate normal 
mouse embryonic development.  It was observed that cells contributing to the 
cardiac lineage arose from cells that stopped expressing Oct4 between days 3 
and 5 in culture (Sajini et al., 2012).   
Oct4 is downregulated first in cells that are committed to a specific 
lineage.  Cells committed to the cardiac lineage should begin to express cardiac-
specific genes at the time that Oct4 expression ceases.  Based on evidence 
presented by Sajini et al., cells downregulating Oct4 between days 3 and 5 were 
  13 
investigated for presence of both early and late cardiac gene expression.  We 
posit that the cells contributing to the PHF and SHF may downregulate Oct4 
expression at different times, which could help to further separate and define the 
individual populations.  By using this double reporter system, cells can be 
separated on the basis of Oct4 expression, and subsequently analyzed for 
expression of genes specific to each heart field.  We expect to see that cells 
contributing to the PHF will downregulate Oct4 expression and begin expressing 
cardiac markers at an early and separate time point from those cells that will 
contribute to the SHF.  
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Materials and Methods 
 
Experimental Design 
 
Induced pluripotent stem (iPS) cells from the Oct4-mTmG reporter line 
were cultured as embryoid bodies (EBs) to mimic embryonic development in vitro 
(Figure 3).  Media was supplemented with tamoxifen for 24-hour pulses on either 
day 3, 4, or 5 to allow for identification of cells either expressing or not expressing 
Oct4 during tamoxifen administration via expression of tdTomato (Oct4-) or eGFP 
(Oct4+) fluorescent proteins.    Following the 24-hour tamoxifen pulse (day 4, 5, 
or 6) or at day 10, the EBs were dissociated into single cells and processed using 
fluorescence-activated cell sorting (FACS).  This allows separation of the cells 
based on Oct4 expression at the time of tamoxifen administration.  The sorted 
populations were immediately collected for RNA analysis using quantitative 
polymerase chain reaction (qPCR) to measure relative RNA expression levels.  
We looked for expression of specific transcripts, like Nkx-2.5 and Isl1, at early 
stages of cardiac differentiation to determine if commitment could be determined.  
Transcripts for structural proteins like cardiac troponin-T (cTnT) and myosin 
heavy chain-6 (Myh6) indicate a more terminally differentiated cardiomyocyte and 
can be quantified by analysis of day 10 samples.  Expression of structural 
proteins and transcription factors was confirmed using immunohistochemistry in 
adherent EBs.  Far red secondary antibodies were used since the membranes of 
the cells were already fluorescent with either tdTomato or eGFP proteins.  
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Figure 3. Experimental Design. MEFs cultured prior to introduction of iPS cells.  After EB 
formation and collection, TMX administered to EBs for 24 hour pulse beginning on either day 3, 4, 
or 5.  Subsequent to TMX removal, EBs either dissociated and processed via FACS sorting, or 
continued on in culture until day 10 before FACS sorting.  Sorted populations were analyzed by 
qPCR. 
 
Preparation of Embryoid Bodies 
 
All medium described in body of text were filtered using 0.22 µl Vacuum 
Filtration Flasks (Denville) and/or Luer-Lok sterile syringes (BD Falcon) before 
use to remove bacteria and other possible contaminants.   
MEF/iPS Cell Culture 
Mouse embryonic fibroblast (MEF) medium was made with DMEM high 
glucose (Gibco).  The DMEM was supplemented with 10% fetal bovine serum 
(FBS) (HyClone), 1% L-glutamine 200 mM (Gibco), 1% anti-anti (antibiotic-
antifungal) (Gibco), and 1% MEM non-essential amino acids (NEAA) (Gibco).  
After MEF medium was prepared, it was stored at 4˚C and discarded within 2 
weeks of the preparation date.  
 Embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) 
medium (ES media) was made with knockout DMEM (KO DMEM) (Gibco).  The 
KO DMEM was supplemented with 10% FBS (HyClone), 10% knockout serum 
replacer (KSR) (Gibco), 1% L-glutamine 200 mM (Gibco), 1% anti-anti (Gibco), 
1% MEM NEAA (Gibco), 0.05 mM β-mercaptoethanol (Gibco, 55mM stock), and 
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1000 units/mL ESGRO-mouse leukemia inhibiting factor (mLIF) (Millipore).  mLIF 
was only added to medium as needed, in smaller aliquots (i.e. 20mL of the 
250mL of media), as it expired much more quickly than basal medium.  Prepared 
ES medium was stored at 4˚C.  Prepared ES (ES-) medium was discarded within 
2 weeks, and ES medium containing mLIF (ES+) was discarded after 5 days.   
Cell freezing (CF) medium was prepared with 80% FBS (HyClone) and 
20% dimethyl sulfoxide (DMSO) (Sigma).  CF medium was prepared as needed, 
and remaining media was discarded the same day.   
Oct4-CreER, mTmG iPS cells (line 3F10) were thawed after having been 
frozen in liquid nitrogen.  3F10 cells between passage 12 and 25 were used in 
experiments.  To thaw the cells, the vials were placed in a pre-warmed water 
bath, set at 37˚C.  Cells were resuspended in ES- medium and spun in a 
centrifuge at approximately 900 rmp for 5 minutes.  This step is important to 
remove the DMSO as it is toxic to the cells.  The remaining pellet was then 
resuspended in ES+ medium and plated onto a monolayer of MEFs on 6-well 
plates (Nest).  MEFs were thawed and plated as above, but with MEF medium.  
The MEFs were plated at a density of 200,000-250,000 cells per well 
approximately 24 hours prior to the thaw of iPS cells to provide a stable 
environment in which iPS cells would retain pluripotency.  All cultured cells (iPS 
and MEFs) were maintained in a stable environment at 37˚C and 5% CO2.  The 
medium was changed the day after cells were plated, to rid the wells of dead 
cells and debris.  Once iPS cells reached near confluence (between days 2 and 
4), cells were washed gently with phosphate buffered saline (PBS) (Cellgro) to 
remove remaining medium.  Cells were then incubated with 0.25% Trypsin-EDTA 
(Gibco) at 37˚C for 5 minutes to break down the attachments formed between the 
cells and with the plate surface.  To neutralize the trypsin, ES- was used to wash 
the cells.  After collection, the cells were spun at 900 rpm for 5 minutes and 
resuspended in ES+.  Cells (MEFs and iPS cells together) were either transferred 
to another well to continue culture, or frozen for storage.  Cells to be frozen were 
resuspended with half ES medium and half CF medium, for a final concentration 
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of 10% DMSO.  The cells were aliquoted into cryovials (Nunc) and stored at -
80˚C for at least 24 hours, and then transferred to liquid nitrogen storage.   
Embryoid Body Formation and Culture 
Differentiation (DM) medium was made with KO DMEM supplemented 
with 15% FBS (HyClone), 1% L-glutamine 200 mM (Gibco), 1% MEM NEAA 
(Gibco), 1% anti-anti (Gibco), and 0.05 β-mercaptoethanol (Gibco, 55 mM stock).   
After preparation, medium was stored at 4˚C and discarded within two weeks of 
preparation date.   
iPS cells from the 3F10 line were cultured as described above.  To form 
embryoid bodies, cells were passaged and dissociated to a single-cell 
suspension as described, and then a feeder depletion step was utilized to 
separate the cells that would not participate in the embryoid body (EB) formation 
from the pluripotent cells (i.e. MEFs and differentiated iPS cells).  This step 
consisted of culturing the cells on a gelatin-coated 6-well culture plate for 
between 35 and 45 minutes at 37˚C and 5% CO2 in ES+/- medium (50-50 
mixture).  In this time, differentiated cells are more likely to adhere to the place 
surface, while pluripotent cells remain in suspension.  After the allotted time, cells 
were gently collected and spun at 900 rpm for 5 minutes and resuspended in DM.  
An aliquot of the suspension was removed and counted utilizing a 
hemocytometer (Bright-line).  Roughly 100,000 cells were used per 15 cm dish 
(Denville) to generate 500-cell EBs.  Cells were resuspended in DM medium at a 
concentration that would yield 500 (+/- 10%) cells per 20 µL.  The suspension 
was transferred to a 25 mL reagent well.  Using 10 channels of a 12-channel 
multichannel pipette (p200, Gilson), 20 µL drops were made on the lid of 15 cm 
dishes.  Between 150 and 190 drops were made per lid.  Dishes were inverted so 
that the drops hung from the lid at 37˚C and 5% CO2.  EBs were collected 
between 24 and 30 hours after formation.  The EBs were collected by washing 
the cells off of the lid surface with DM medium and transferred to 15 mL conical 
tubes.  After allowing the EBs to settle for approximately 5 minutes, excess 
medium was removed.  The EBs were resuspended gently in approximately 2 mL 
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of DM medium and transferred to a 6-well tissue culture plate.  Between 180 and 
300 EBs were cultured per well.  Medium in the wells was changed every 2 days 
by removing half of the medium and supplying fresh medium.   
Tamoxifen Administration 
Z-4-hydroxytamoxifen (Sigma) was dissolved in DMSO at a concentration 
of 0.1 mM.  This stock was diluted again using DMSO to a final concentration of 
100 nM.  Medium was supplemented with tamoxifen using 1µL of tamoxifen per 
mL of DM medium, and was filtered using a Luer-Lok syringe prior to use.   
DM medium supplemented with tamoxifen (TDM), resulting in a final 
concentration of 0.1nM, was used to culture EBs at the indicated time points 
noted previously in the same manner as DM medium.  TDM was only 
administered once and left in contact with cells for 24 hour periods, to identify the 
cells either expressing Oct4 or cells that no longer expressed Oct4 at some point 
during the 24 hour window.  When TDM medium was introduced or removed, all 
of the medium from the well was changed.  Cells were either sorted immediately 
after the 24 hour pulse, or continued on in culture until day ten.  Cells that 
remained in culture were first washed with PBS to remove any trace TDM 
medium, and were supplied with fresh DM medium.   
 
Fluorescence Activated Cell Sorting 
 
Tamoxifen-treated EBs were dissociated using 0.25% Trypsin-EDTA 
(Gibco) to a single-cell suspension and neutralized with DM medium.  The 
suspension was centrifuged at 900 rpm for 5 minutes, and the medium containing 
trypsin was removed.  Cells were resuspended with PBS (Cellgro) and 
centrifuged at 900 rmp for 4 minutes, twice, to remove all medium from the 
suspension.  Cells were then resuspended in FACS buffer (PBS-0.02%FBS, 
filtered with Luer-Lok syringe) and filtered through cell-strainer caps into 5ml 
polystyrene round-bottom tubes (35 µm, BD Falcon).  The dissociated EBs were 
sorted and analyzed using FACS Aria.  For fluorophore controls, 3F10 cells with 
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no history of tamoxifen were used to gate the tdTomato+ cells, and 3F10 cells 
given tamoxifen in a pluripotent state were used to set the gate for eGFP+ cells.  
Fluorescence activated cell sorting (FACS) was utilized to separate cells either 
expressing Oct4 (eGFP+) or not expressing Oct4 (tdTomato+/eGFP-) from a 
single population.  RNA from the sorted populations of cells was isolated using 
RNeasy Mini Kit (Qiagen), and cDNA was generated from the RNA and analyzed 
by quantitative polymerase chain reaction (qPCR).   
 
RNA and cDNA Preparation 
 
Cells and EBs to be analyzed by qPCR were dissociated into single-cell 
suspensions as described above.  After centrifugation at 900 rpm for 5 minutes, 
medium was removed from the cells.  The pellet of a sample was resuspended in 
350 µL of RLT Lysis Buffer with 1% β-mercaptoethanol and collected in a 1.5 mL 
eppendorf tube.  Samples were immediately stored at -20˚C until processed. 
To extract total RNA, samples were thawed at room temperature (RT).  A 31G 
syringe (BD Falcon) was used to homogenize the sample by drawing the sample 
up and expelling it between 3 and 5 times.  RNA was extracted through a series 
of washes using RNeasy Mini Kit (Qiagen) and stored at -20˚C.   
cDNA was generated from total RNA using random hexamer primers (50 
ng/µL), dNTP mix (10 mM), and SuperScript II Reverse Transcriptase 
(Invitrogen).  After preparation, samples were stored at -20˚C.   
 
E12 Embryo Isolation 
 
To provide a positive RNA control for qPCR, embryonic day 12 (E12) 
embryos were isolated from pregnant female mice.  E12 was chosen as the 
genes of the mature structural proteins should be expressed, as should the 
transcription factors specific to the cells of the individual heart fields.  The mice 
were sacrificed and dissected to extract the embryos from the womb.  Embryos 
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were washed with PBS in two separate petri dishes to clear the field of blood for 
dissection.  The hearts were isolated from the remainder of the embryos.  The 
hearts were stored in RLT lysis buffer and processed in a similar fashion to cells 
for collection of RNA (i.e. use of insulin need to homogenize sample).   
 
Quantitative Polymerase Chain Reaction (qPCR) 
 
Gene expression of populations expressing and not expressing Oct4 and 
the time of tamoxifen administration was measured using quantitative 
polymerase chain reactions (qPCR).  Relative gene expression measurement of 
the two populations included the following genes: cardiac Troponin-T (cTnT), 
Islet1 (Isl1), Nkx2.5, Flk1, PDGFRα, Troponin-I (Tnni), Tbx1, Tbx5, Myosin light 
chain-2 (Myl2), Myosin heavy chain-6 (Myh6), and housekeeping gene Gapdh.  
All qPCR reactions were repeated with three technical replicates, and three 
biological replicates when possible.  The Eppendorf RealPlex2 Mastercycler was 
used for all qPCR reactions with 40 cycles, with predesigned primers from IDT 
(Table 1) and SYBR Green Master Mix (Applied Biosystems).  SYBR Green 
preferentially binds to double-stranded DNA and fluoresces, which is formed 
when the primers bind to the target transcript of cDNA.  All primers were verified 
by melting curve analysis at least three separate times.   
Relative expression (2^dct) was analyzed for all relevant data points using 
JMP Pro 10 software.  Two datasets were compared during each analysis 
(i.e.Oct4+ vs. Oct4- for a specific time point).  Mean, standard deviation, and t-
test analyses were run for each comparison to determine statistical significance.  
Error bars on graphs were calculated using standard error from the mean.   
 
Agarose Gel Preparation 
 
Samples were run on agaraose gels when threshold cycle (Ct) values 
were observed in qPCR reactions that differed noticeably from identical or similar 
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reactions.  SYBR Green in the qPCR reaction recognizes and binds to double-
stranded DNA formed by the IDT primer and the cDNA, as described above.  
Occasionally, primer dimers can form, in which the forward and reverse primers 
bind to each other.  Primer dimers are also recognized by SYBR green, because 
it is not specific for primer-cDNA reactions.  Primer dimers can cause 
fluorescence to be detected at a much earlier cycle than valid expression levels.  
When a PCR product is run on a gel, the size of the product can be determined.  
Average amplicon sizes should be approximately 100 base pairs (bp); anything 
significantly larger or smaller may provide evidence to discount the observed Ct 
value.   
1.5% Ultrapure agarose (Invitrogen) gels were used to visualize the 
double-stranded DNA present in a sample. One gram of agarose is equivalent to 
1% in 100mL of buffer.  The buffer used was 1x TAE buffer (stock 50x Tris/Acetic 
Acid/EDTA buffer diluted) (BioRad).  1.5% agarose was added to buffer solution, 
and heated to dissolve the powder.  Ethidium bromide (Sigma) was added to the 
solution to allow for visualization of the DNA bands.  The solution cooled in a rack 
until solidified.  Gels were placed in a bath of TAE buffer in the horizontal unit of 
the electrophoresis system (FisherBiotech).  DNA ladder (100 kb, Promega) was 
added as a control lane.  Blue-orange loading dye (Promega) was added to 
samples, and the mixture was loaded into lanes.  The gel was run at 
approximately 115mv (Electrophoresis System, FisherBiotech) until the rungs of 
the ladder were separated enough to be distinct from one another.  The gel was 
visualized using the GelDoc System and imager (Biorad), and images were 
subsequently analyzed to determine the size of the amplified transcripts and 
hence the validity of the Ct value of the sample.   
 
Immunohistochemistry 
 
Embryoid bodies (EBs) were collected from 15cm dishes and 
resuspended in DM medium.  Approximately 35 to 50 EBs were plated on 
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gelatin-coated 4-chamber well slides (BD Falcon).  Tamoxifen administration took 
place on days 3, 4, and 5, as described previously.  Adherent EBs were cultured 
on the slides, with regular medium changes as previously described, until day 10.  
On day 10, EBs in the wells were first washed gently with PBS (Cellgro) and then 
fixed with 0.2% PFA (Sigma) for 10 minutes to preserve the structural integrity of 
the cells.  Wells were again washed with PBS (Cellgro) three times to remove the 
PFA from contact with the samples.  Cells were permeabilized using PBS-0.5% 
Triton (Sigma) (PBS-T) for 10 minutes.  5% normal donkey serum (Jackson 
Laboratories) in PBS-T was used to block samples for one hour.  Samples were 
incubated overnight at 4˚ with the following primary antibodies diluted in PBS 
blocking buffer with 5% donkey serum: cTnT (CT3-s, 1:250; DSHB) and Isl1 
(40.3A4, 1:500; DSHB), both raised in mouse.  Wells were washed three times 
with PBS to remove excess antibody, and reblocked with PBS-donkey blocking 
serum for one hour.  Next, adherent EBs were incubated at room temperature for 
2 hours with the secondary antibody diluted in PBS-donkey blocking serum.  Cy5 
anti-mouse antibody (A10524, 1:1000, Invitrogen) was used.  Wells with no 
primary antibody and only secondary antibody administration were used as 
negative controls.  Subsequently, wells were washed with PBS for 15 minutes 
three times before mounting.  Slides were mounted with Vectashield containing 
DAPI (Vector Labs).  After processing, slides were analyzed using the Olympus 
FluoView FV1000 Inverted Confocal with FLIM detector using IP Lab software.   
Immunohistochemistry was performed on one round of embryoid bodies 
(EBs) with three separate slides for each time point.  Quantification was 
calculated by counting the total number of cells positive for each antibody on 
three separate patches for each antibody for each time point.  From this total, the 
percent that were positive for tdTomato and eGFP were recorded and used to 
generate an average proportion for the time point.  
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Results 
 
Oct4 is downregulated during development 
 
 In the developing embryo, Oct4 is initially expressed by all cells in the 
inner cell mass (ICM) and is subsequently shut off as cells commit to different 
lineages (Kehler et al., 2004; Niwa et al., 2000).  As demonstrated by Sajini et al. 
in 2012, EBs made with iPS cells from the 3F10 Oct4-mTmG reporter line 
faithfully recapitulate the developing embryo in that they downregulate Oct4 in a 
similar fashion.  Cells expressing Oct4 at the time of tamoxifen administration will 
excise tdTomato from the genome, and will express eGFP only.  Cells that have 
stopped expressing Oct4 when tamoxifen is administered will not have Cre-
recombinase present to remove the sequence, and those cells will only express 
tdTomato.  We expected to see a sharp down regulation of Oct4 between days 3 
and 5 in culture of EBs.  When analyzed by FACS, this hypothesis was confirmed 
(Figure 4).  The majority of cells were still expressing Oct4 when tamoxifen was 
present in the media on day 3.  More than half of the cells had downregulated 
Oct4 at the time of tamoxifen administration on day 4, and the majority had 
ceased to express Oct4 at day 5.  This confirmed that cells are indeed 
downregulating Oct4 in the iPS-derived EBs as would be expected in 
development.   
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Figure 4. Proportion of Cells Expressing Oct4 
Average proportion of cells expressing tdTomato (Oct4-) or eGFP (Oct4+) from FACS sorting 
analysis.  The majority of cells are still expressing Oct4 at day 3, but Oct4 is downregulated in the 
vast majority of cells by day 5.  This temporal pattern was similar, regardless of whether the sort 
was done 24 hours later or on day 10 of culture.  The values represent the mean percentage of 
Oct4+/- cells for 3 sorts for d3 and d5, and four sorts for d4, d3-10, d4-10, and d5-10.  
 
Cells Expressing Cardiac-Specific Genes Arise from Cells that Turn Off 
Oct4 Between Days 4 and 5 
 
 Based on data from Sajini et al. in 2012, we hypothesized that cells that 
cease to express Oct4 between days 4 and 5 are the population from which 
cardiac cells originate.  To test this theory, EBs were cultured on culture well 
slides from collection until day 10.  Spontaneous beating was observed in cells 
by day 8 of culture (Data not shown).  Day 10 was selected as an endpoint to 
allow further maturation of these cells.  On day 10, they were fixed and stained 
with antibodies recognizing Islet1 (Isl1), which is fairly specific to the secondary 
heart field in cardiac development (Van Vliet et al., 2012; Buckingham et al., 
2005), and cardiac troponinT (cTnT), which is expressed in mature 
cardiomyocytes (Bondue et al., 2011).   
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Figure 5. Quantification of Immunohistochemistry for Isl1 antibody 
Calculated by proportion of cells positive for Isl1 antibody and either eGFP or tdTomato for the 
three time points. Three separate patches positive for the antibody were counted.   
 
 Cells expressing Isl1 on day 10 mostly originate (on average 98%, Figure 
5) from cells expressing Oct4 on day 3 (Figure 6).  Cells positive for eGFP had 
the polycistronic Oct4-MerCreMer transcript present at the same time as the 
tamoxifen was introduced in order to cause excision of the tdTomato sequence, 
and induce expression of eGFP.  In the image shown in Figure 6, there are no 
cells expressing Isl1 that are also expressing tdTomato (Oct4-). These data imply 
that cells contributing to the secondary heart field (SHF) nearly all express Oct4 
on day 3 of culture.  By day 4 of culture, cells still expressing Oct4 give rise to the 
majority (approximately 81%, Figure 5) of the Isl1+ population on day 10 (Figure 
7).  This indicates that some of the Isl1+ cells on day 10 had stopped expressing 
Oct4 by day 4.  In Figure 7, it is apparent that many cells are coexpressing eGFP 
and tdTomato.  Since the cells are expressing eGFP at all, it means that the 
Oct4-MerCreMer transcript was present at the time of tamoxifen administration.  
tdTomato expression would have ceased, but the resultant fluorescent protein 
may not have been fully degraded in the cells in Figure 7 on day 10 before 
fixation.  However, the majority of cells expressing Isl1 on day 10 (approximately 
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90%) originate from the Oct4- population of day 5 (Figure 5 and Figure 8).  These 
data suggest that cells expressing Isl1 on day 10 quickly cease to express Oct4 
between days 4 and 5.  It should be noted in this system that although tamoxifen 
is present for a full 24 hours, most of the recombination can occur within 6 hours 
of tamoxifen introduction.  This means that cells that are expressing eGFP on 
day 4 could have been expressing Oct4 at day 4.0, but may have ceased 
expression by day 4.5.  Since eGFP expression is permanent and irreversible, it 
is not possible to determine if this was the case.    
 
Figure 6. Isl1+ cells arise from cells expressing Oct4 on day 3 
EBs with medium supplemented with tamoxifen on day 3 of culture immunostained with Isl1 
antibody on day 10 of culture.  Nearly all patches of cells expressing Isl1 were still expressing 
Oct4 during tamoxifen administration.  A. DAPI with Oct4+ (eGFP). B. Oct4- (tdTomato). C. Isl1. 
D. Merge.  Scale bar 50µm. 
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Figure 7. Isl1+ cells generally arise from cells still expressing Oct4 on day 4 EBs with 
medium supplemented with tamoxifen on day 4 of culture immunostained with Isl1 antibody on 
day 10 of culture.  Most cells expressing Isl1 were still expressing Oct4 during tamoxifen 
administration.  A. DAPI with Oct4+ (eGFP). B. Oct4- (tdTomato). C. Isl1. D. Merge.   Scale bar 
50µm. 
 
Figure 8. Isl1+ cells generally arise from cells not expressing Oct4 on day 5  
EBs with medium supplemented with tamoxifen on day 5 of culture immunostained with Isl1 
antibody on day 10 of culture.  Almost all cells expressing Isl1 were not expressing Oct4 during 
tamoxifen administration.  A. DAPI with Oct4+ (eGFP). B. Oct4- (tdTomato). C. Isl1. D. Merge.    
Scale bar 50µm.  
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Figure 9. Quantification of Immunohistochemistry for cTnT antibody 
Calculated by proportion of cells positive for cTnT antibody and either eGFP or tdTomato for the 
three time points. Three separate patches positive for the antibody were counted.   
 
 Similar to the observations of Isl1 immuno-positive cells, the majority 
(approximately 83%, Figure 9) of cells expressing cTnT at day 10 were also 
expressing Oct4 on day 3 of culture (Figure 10).  Cells that will commit to the 
cardiac lineage cease Oct4 expression at a later time point than day 3 of culture. 
By day 4 of culture, cells expressing cTnT originate from both Oct4- and Oct4+ 
populations, with approximately 60% being Oct4- and 40% Oct4+ (Figure 9 and 
Figure 11).  At day 10 of culture, cells expressing cTnT had nearly all (96%, 
Figure 9) stopped expressing Oct4 by day 5, indicated by the persistence of 
tdTomato proteins in the membrane (Figure 12) 
  29 
Figure 10. cTnT+ cells arise from cells expressing Oct4 on day 3 
EBs with medium supplemented with tamoxifen on day 3 of culture stained with cTnT antibody on 
day 10 of culture. Nearly all of cells expressing cTnT were still expressing Oct4 during tamoxifen 
administration. A. DAPI with Oct4+ (eGFP). B. Oct4- (tdTomato). C. cTnT. D. Merge. Scale bar 
100µm.   
 
Figure 11. cTnT+ cells arise from cells both expressing and not expressing Oct4 on day 4  
EBs with medium supplemented with tamoxifen on day 4 of culture stained with cTnT antibody on 
day 10 of culture.  Most cells expressing cTnT were not expressing Oct4 during tamoxifen 
administration. A. DAPI with Oct4+ (eGFP). B. Oct4- (tdTomato). C. cTnT. D. Merge.  Scale bar 
100µm.  
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Figure 12. cTnT+ cells arise mostly from cells not expressing Oct4 on day 5 
EBs with medium supplemented with tamoxifen on day 5 of culture stained with cTnT antibody on 
day 10 of culture.  Almost all cells expressing cTnT were not expressing Oct4 during tamoxifen 
administration. A. DAPI with Oct4+ (eGFP). B. Oct4- (tdTomato). C. cTnT. D. Merge.   Scale bar 
100µm. 
 
These data from immunostaining when taken together indicate that cells 
expressing cTnT at day 10 downregulated Oct4 earlier than cells expressing Isl1 
at day 10.  Isl1 is generally expressed in the SHF, which contributes to heart 
development at a slightly later time than the primary heart field (PHF) does.  The 
PHF progenitors contribute to the inflow tract, atria, and left ventricle and the SHF 
progenitors develop into the outflow tract and right ventricle (Abu-Issa and Kirby, 
2007; Vincent and Buckingham, 2010). Cardiomyocytes comprising atria and 
ventricles are the cells responsible for contracting to expel blood from the heart, 
and will all express cTnT.  Since both atria and the left ventricle will express 
cTnT, it is not surprising to see more cells that have shut off Oct4 expression 
which are also cTnT+, as these cells may be part of the PHF.  The cells from the 
Isl1+ SHF that comprise the right ventricle may still be expressing Oct4 at this 
point.  Immunostaining of the PHF was attempted with and Nkx2.5 antibody, but 
was unsuccessfully optimized.   
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Preliminary qPCR Data 
 
 To further characterize the development of cardiac cells and the role of 
Oct4 in lineage commitment, FACS was used to separate eGFP-expressing cells 
from tdTomato-expressing cells and these populations were analyzed using 
quantitative polymerase chain reactions (qPCR).  Samples were sorted either 
immediately following the 24-hour tamoxifen window, or on day 10 of culture.  
Cells were processed for RNA collection immediately following sorting.  Primers 
were used to target the following genes, which are known to play a role in cardiac 
differentiation (Figure 1): PDGFRa, Flk1, Nkx2.5, Tbx5, Isl1, Tbx1, cTnT, Tnni, 
Myl2, and Myh6 (Van Vliet et al., 2012; Stefanovic et al., 2009; Rana et al., 2013; 
Bondue et al., 2011).  In the sorts immediately following tamoxifen administration, 
we hypothesized that we may see differential expression between Oct4 
expressing and nonexpressing populations for genes known to be upregulated in 
early specification to the cardiac lineage (Nkx2.5 & Tbx5 in the PHF, Isl1 &Tbx1 
in the SHF).  In samples sorted on day 10, we hypothesized that a difference in 
expression between populations either expressing or not expressing Oct4 may 
be observed in the more terminally expressed genes (cTnT, Tnni, Myl2, and 
Myh6), as these are structural proteins and would not be present in progenitors.  
For comparison, qPCR was also performed on RNA samples from iPS cells 
collected during passaging and from cells from murine embryonic day 12 (E12) 
heart.  The E12 serves as a positive control for the gene expression of a 
terminally differentiated cell, but some of the earlier genes required for 
development may also be expressed in this more mature tissue.  It should be 
noted that this data is preliminary, given the small and varied sample sizes 
(Table 2, Appendix).  Additional replicates are necessary for more data in order 
to draw confident conclusions. 
Figure 13 illustrates the results of the PCR performed on RNA from cells 
sorted after 24-hours tamoxifen administration.  EBs were given tamoxifen for 24 
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hours on day 3, 4, or 5, and subsequently sorted on day 4, 5, or 6.  The 
population no longer expressing Oct4 on day 5 expressed myocardial progenitor 
marker PDGFRa at a significantly higher level than on day 3 (Figure 13A).  
PDGFRa was expressed at approximately 10-fold higher than in the day 0 iPS 
cells; Flk1 was also expressed in the sorted populations and not in the day 0 iPS 
cells (Figure 13A).  The primary heart field (PHF) can be distinguished from the 
SHF by expression of Nkx2.5 and Tbx5 (Rana et al., 2013). Nkx2.5 expression 
was higher in Oct4- cells on day 5 than on day 4 (Figure 13B).  Nkx2.5 is also 
expressed in other regions of the heart, but it is more uniformly expressed by the 
PHF.  The secondary heart field (SHF) is identified by expression of transcription 
factors Isl1 and Tbx1 (Buckingham et al., 2005).  Tbx1 was significantly 
upregulated in Oct4- cells in comparison to Oct4+ positive cells on day 4, 
indicating that the SHF may indeed originate from cells that stop Oct4 expression 
on day 4 (Figure 13C).  Isl1, on the other hand, was expressed at a higher level 
in the population of cells still expressing Oct4 on day 4 (Figure 13C). 
It should also be pointed out that the Isl1 expression observed in these 
early time points is roughly equivalent to the expression level in the day 0 iPS 
cells.  With that in mind, one must question whether the expression level in the 
sorted populations is anything more than basal expression in this cell line.  
Expression of other genes are also observed in the day 0 pluripotent cells 
(PDGFRa, Tbx5, cTnT, and Isl1).  These unusual expression profiles have also 
been observed by others in the same pluripotent cell line (personal 
communication; Lucas Greder and Sarah Burley).  Expression levels of cTnT at 
these early time points were low relative to an E12 heart, which is consistent with 
the expected expression of cTnT in more mature cardiomyocytes (Figure 13D). 
These markers for cardiac progenitors, with the exception of Tbx1, were 
expressed at a fraction of the level of expression in the E12 heart, perhaps 
indicating that they have not yet been upregulated (Figure 13).  
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Figure 13. 
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Figure 13. Gene expression analysis of 24 Hour Pulse Sorts  
qPCR data from cells sorted 24 hours after tamoxifen was introduced into culture media. A. 
Genes expressed in myocardial progenitors.  B. Genes expressed in the PHF. C. Genes 
expressed in the SHF. D. A gradual increase of expression of cTnT is observed as the cells 
progress through differentiation.  Statistical significance (p>0.05) is denoted by * and error bars 
show standard error of the mean.  Numerical values at the base of the E12 bars are the exact 
relative expression value, since the proportion of the graphs would be skewed if the entire bar 
were included.   
 
Figure 14 illustrates the results from cells sorted on day 10 of culture, after 
tamoxifen was supplied for 24-hour pulses on either day 3, 4, or 5.  With these 
sorts, there were some cell samples that did not survive the FACS sorting to be 
analyzed.  These populations (Oct4- from day 3 and Oct4+ from day 5) were not 
run in triplicate (see Table 2 in appendix for sample sizes), and standard error 
could not be calculated.  The preliminary data is still shown on the graphs in 
Figure 14, but given the small sample sizes it is inconclusive as of yet.  In order 
to be fully functional, mature cardiomyocytes must express genes encoding 
structural proteins responsible for contraction, such as Myl2, Myh6, Tnni, and 
cTnT (Lui et al., 2007).  These proteins were upregulated relative to iPS cells, but 
lower than expression in the E12 heart at day 10 (Figure 14A), suggesting that 
they are not yet mature.  This lower expression of mature markers could also be 
attributed to the heterogeneous nature of the cell populations.  Since qPCR 
calculates the average transcripts per cell based on the entire population, the 
cells expressing these structural proteins in Figure 14A may be expressing high 
levels but these cells may only represent a small fraction of the total cell 
population.  
Genes specific to the PHF (Figure 14B) and SHF (Figure 14C) were 
present in both Oct4+ and Oct4- populations sorted on day 10, but there were no 
statistically significant differences in expression.  Expression of Isl1 increased 10-
fold in comparison to the expression on days 4, 5, and 6 (Figure 13C and Figure 
14C).  Although there is no significant difference between the Oct4+ and Oct4- 
populations in the day 10 sorts, the Isl1 expression level for all populations is 
relatively similar to the E12 heart expression (Figure 14C).  The expression level 
of Tbx1 is higher in the sorted populations in comparison to the E12 heart.  
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Perhaps the Tbx1 expression is just increasing in expression in these sorted 
populations, before it decreases in the mature tissue.  
  36 
Figure 14.
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Figure 14. Gene Expression Analysis of Sorted Day 10 Populations  
qPCR data from cells sorted on day 10 of culture when tamoxifen was administered for 24 hours 
on either day 3, 4, or 5. A. Genes expressed in mature cardiomyocytes. B. Genes expressed in 
the PHF. C. Genes expressed in the SHF. Statistical significance (p>0.05) is denoted by * and 
error bars show standard error of the mean.  Numerical values at the base of the E12 bars are 
the exact relative expression values, since the proportion of the graphs would be skewed if the 
entire bars were included.   
 
To determine the expression patterns of the genes of interest, samples 
were collected for RNA analysis on the same day as experimental populations 
were sorted, but were never supplied tamoxifen, and subsequently analyzed 
using qPCR.  In earlier progenitors, one would not expect to see expression of 
structural proteins of mature cardiomyocytes.  This was confirmed in Figure 15A.  
Expression levels of these genes were much higher at day 10 than either day 3, 
4, or 5.  Transcription factors demarcating the PHF and SHF from one another 
were also expressed at higher levels in cells sorted on day 10 (Figure 15B and 
Figure 15C).  Isl1 is expressed on day 10 at a level similar to the E12 heart, and 
Tbx1 is expressed at a level higher than the E12 heart, which was previously 
stated.   
It should be noted that some gene expression could be attributed to 
contamination from expression in other cell types in many of these markers.  Isl1 
is also expressed in developing pancreatic and neural tissues (Habener et al., 
2005).  Tbx1 functions in artery and gland development, as well as the cardiac 
development (Ryan and Chin, 2003; Scambler, 2010).  Tbx5 not only plays a role 
in cardiac differentiation, but also limb specification (Oberg, 2013).  Day 10 in 
culture may also be when these transcription factors are expressed in the cardiac 
lineage progression in this EB system with this cell line.   
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Figure 15. 
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Figure 15. Gene Expression Analysis of Unsorted Populations 
qPCR data from cells collected on the same day that experimental populations were sorted, but 
were not given tamoxifen at any time. A. Gene expression levels of structural proteins in mature 
cardiomyocytes. B. Genes expressed in PHF. C. Gene expressed in SHF.  Error bars show 
standard error of the mean.  Early time points (days 4, 5, and 6) differing significantly (p>0.05) 
from the later time point (**, day 10) are demarcated by *.  Numerical values at the base of the 
E12 bars are the exact relative expression values, since the proportion of the graphs would be 
skewed if the entire bars were included.   
  
With such large standard error observed in the qPCR data, it is quite 
difficult to make any conclusions from the data at present with any certainty.  
Perhaps with more biological replicates, conclusions may be drawn with 
confidence.  The expanded list of samples sizes is in Table 2 of the appendix.   
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Discussion  
 
The intention of these experiments was to explore the possibility that the 
primary (PHF) and secondary heart fields (SHF) may cease to express Oct4 at 
different times.  We hypothesized that the PHF would shut off expression of Oct4 
before the SHF because the cells contributing to the PHF commit to the cardiac 
lineage before those of the SHF.  Generally, cells that are differentiating do not 
express Oct4, except for in primordial germ cells and oocytes (Scholer et al., 
1990).   
The data gathered from immunohistochemistry suggests that cells 
committing to the cardiac lineage mostly cease to express Oct4 between days 4 
and 5 of culture.  We found that cells that express cTnT at day 10 stopped 
expressing Oct4 mostly between days 4 and 5 of culture, which is similar to what 
was observed by Sajini et al. in 2012.  The methods used in this thesis were 
similar to Sajini et al. in nearly all aspects with two exceptions.  EBs in this thesis 
were formed via hanging drop method instead of the spin method, and were not 
cultured in suspension but instead were adherent to the culture well surface.  
EBs grown in suspension differentiate into all lineages, while EBs grown 
adherent to surfaces tend to differentiate into muscle and neuronal lineages 
(Kehler et al., 1995).  Sajini et al. only identified cardiomyocytes by cTnT 
immunostaining, whereas we used an additional marker.  Our data from 
immunostaining using the Isl1 antibody implies that cells contributing to the 
secondary heart field (SHF) stop Oct4 expression before day 5, but sometime 
after tamoxifen administration on day 4.  An antibody identifying a marker of the 
PHF (Nkx2.5) was also used, but the background fluorescence and nonspecific 
binding prevented inclusion of the resulting data.   
Preliminary qPCR data demonstrates that the genes of interest do 
increase in expression over time in 3F10 iPS-derived EBs.  However, the data 
gathered has large variability between replicates in the qPCR analysis, which 
makes it difficult to draw any conclusions of significance from this data alone.  As 
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previously suggested, more replicates may help to decrease standard error from 
mean, and establish more representative expression levels for each time point.  
Since qPCR is a relative measure of transcript per cell, it yields an average 
across the entire population.  When analyzing qPCR results, one must consider 
that if a 10-fold increase is observed, it could be attributed to a few cells 
expressing high levels of transcript, or many cells expressing at intermediate 
levels.  Both of our sorted populations are comprised of cell types at different 
stages of differentiation toward different lineages, therefore an average 
measurement could obscure the expression level of cells in our specific 
population of interest (i.e. PHF and SHF).  Taken all together, the collective data 
does suggest that cells committing to the cardiac lineage generally cease to 
express Oct4 between days 4 and 5 of culture.   
An alternative approach to answer the same question may be to use a 
different iPS reporter line, or multiple reporter lines.  If Oct4 expression was 
labeled by only a single fluorophore, like eGFP, when in the presence of 
tamoxifen, then a second fluorophore could be utilized to identify cells specific to 
the cardiac lineage.  By choosing a gene expressed at a specific time in 
development (i.e. Nkx2.5 in early stages or cTnT later in commitment) to also 
express tdTomato from the endogenous locus, then a more specific population 
may be isolated.  For example, a cell line with an Oct4-CreER inducing 
expression of eGFP and tdTomato driven by the Nkx2.5 promoter could be used 
to identify cells as they commit to the PHF around day 6 of culture.  A cell line 
expressing an Oct4-CreER (with eGFP expressed in the presence of tamoxifen) 
and tdTomato driven by expression of cTnT could be used to separate cells as 
they become more mature cardiomyocytes around day 10.  By default, cells not 
expressing eGFP but expressing tdTomato would not be expressing Oct4 at the 
time of tamoxifen administration, but would be contributors to the cardiac lineage.  
Cells could be sorted using FACS based on cTnT expression, and cells with 
eGFP expression also would identify those expressing Oct4 at a specific time.  
FACS could provide a quantitative value of the proportion of cells expressing 
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cTnT in relation to the entire population, and the separated populations 
expressing cTnT would more homogeneous than the sorted populations in this 
thesis.  This way, the populations analyzed by qPCR will not be contaminated 
with cells from other lineages, and will permit a more representative quantification 
of relevant gene expression levels.  This approach would better address the 
question of whether or not Oct4 is turned off at different times in cells that will 
contribute to the PHF and SHF.  Although this approach would require the 
generation of iPS lines from multiple lines of transgenic mice, it would allow for 
more specific isolation of the cell population of interest. 
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Appendix 
 
 
Primer Primer Sequence 
Gadph 
5’ GTG GAG TCA TAC TGG AAC ATG 
TAG 3’ 
3’ AAT GGT GAA GGT CGG TGT G 5’ 
Cardiac Troponin-T 
5’ TCA AAG TCC ACT CTC TCT CCA 3’ 
3’ CTG ATG AAG AAG CCA AAG ATG C 
5’ 
Isl-1 
5’ TCG TTC TTG CTG AAG CCT ATG 3’ 
3’ AAT GTG CGG AGT GTA ATC AGT 5’ 
Nkx2.5 
5’ CAG CTC CAC TGC CTT CTG 3’ 
3’ CCA AGT GCT CTC CTG CTT T 5’ 
Flk1 (KDR) 
5’ GGA TCT TGA GTT CAG ACA TGA 
GG 3’ 
3’ GGA ATT GAC AAG ACA GCG ACT 5’ 
Troponin-I  
5’ TTC TTC CTC CAG TCT CCT ACC 3’ 
3’ CTC TAA GCA CAA GGT GTC CAT 5’ 
Tbx1 
5’ ACA AAG TCC ATG AGC AGC AT 3’ 
3’ GTG GGA CGA GTT CAA TCA GC 5’ 
Tbx5 
5’ CGT CTG CTT TCA CGA TGT GTA 3’ 
3’ CTC AAA CTC ACC AAC AAC CAC 5’ 
Myl2 
5’ GGA AAG GCT GCG AAC ATC T 3’ 
3’ GAC CAT TCT CAA CGC ATT CAA G 
5’ 
Myh6 
5’ CTG GTC CTC CTT TAT GGT CAC 3’ 
3’ GAG TGC TTC GTG CCT GAT 5’ 
PDGFRa 
5’ TCA CAG CCA CCT TCA TTA CAG 3’ 
3’ GTT GCC TTA CGA CTC CAG ATG 5’ 
 
Table 1. List of qPCR Primers. 
List of pre-designed primers from IDT for gene expression analysis via qPCR.  
 
PCR conditions for these primers were as follows: 95˚ for 2 minutes; 40 cycles of 
95˚ for 15 seconds, 59˚ for 15 seconds, and 68˚ for 20 seconds; and melting 
curve step for 95˚ for 15 seconds followed by 20 minutes beginning at 60˚ and 
ending at 95˚ with 15 second intervals at each temperature. 
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Primer Sample n Primer Sample n Primer Sample n Primer Sample n 
cTnT 3 Oct4+ 3 Flk1 3 Oct4+ 4 Tbx5 3 Oct4+ 4 PDGFRa 3 Oct4+ 4 
 3 Oct4- 3  3 Oct4- 2  3 Oct4- 4  3 Oct4- 3 
 
3 No 
Sort 4  
3 No 
Sort 4  
3 No 
Sort 4  
3 No 
Sort 4 
 4 Oct4+ 4  4 Oct4+ 3  4 Oct4+ 4  4 Oct4+ 4 
 4 Oct4- 5  4 Oct4- 3  4 Oct4- 4  4 Oct4- 4 
 
4 No 
Sort 3  
4 No 
Sort 3  
4 No 
Sort 3  
4 No 
Sort 3 
 5 Oct4+ 3  5 Oct4+ 2  5 Oct4+ 3  5 Oct4+ 2 
 5 Oct4- 3  5 Oct4- 3  5 Oct4- 3  5 Oct4- 3 
 
5 No 
Sort 3  
5 No 
Sort 3  
5 No 
Sort 3  
5 No 
Sort 3 
 
3-10 
Oct4+ 4  
3-10 
Oct4+ 4  
3-10 
Oct4+ 4  
3-10 
Oct4+ 4 
 
3-10 
Oct4- 2  
3-10 
Oct4- 1  
3-10 
Oct4- 2  
3-10 
Oct4- 1 
 
4-10 
Oct4+ 4  
4-10 
Oct4+ 3  
4-10 
Oct4+ 4  
4-10 
Oct4+ 4 
 
4-10 
Oct4- 4  
4-10 
Oct4- 4  
4-10 
Oct4- 4  
4-10 
Oct4- 4 
 
5-10 
Oct4+ 3  
5-10 
Oct4+ 1  
5-10 
Oct4+ 1  
5-10 
Oct4+ 1 
 
5-10 
Oct4- 4  
5-10 
Oct4- 4  
5-10 
Oct4- 4  
5-10 
Oct4- 4 
 
Day10 
No Sort 4  
Day10 
No Sort 4  
Day10 
No Sort 4  
Day10 
No Sort 4 
Isl1 3 Oct4+ 4 Tnni 3 Oct4+ 4 Myl2 3 Oct4+ 4 
 3 Oct4- 4  3 Oct4- 2  3 Oct4- 2 
 
3 No 
Sort 4  
3 No 
Sort 4  
3 No 
Sort 4 
 4 Oct4+ 4  4 Oct4+ 4  4 Oct4+ 4 
 4 Oct4- 4  4 Oct4- 3  4 Oct4- 3 
 
4 No 
Sort 3  
4 No 
Sort 3  
4 No 
Sort 3 
 5 Oct4+ 3  5 Oct4+ 3  5 Oct4+ 2 
 5 Oct4- 3  5 Oct4- 3  5 Oct4- 3 
 
5 No 
Sort 3  
5 No 
Sort 3  
5 No 
Sort 3 
 
3-10 
Oct4+ 4  
3-10 
Oct4+ 4  
3-10 
Oct4+ 4 
 
3-10 
Oct4- 2  
3-10 
Oct4- 2  
3-10 
Oct4- 1 
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4-10 
Oct4+ 4  
4-10 
Oct4+ 4  
4-10 
Oct4+ 3 
 
4-10 
Oct4- 4  
4-10 
Oct4- 4  
4-10 
Oct4- 4 
 
5-10 
Oct4+ 2  
5-10 
Oct4+ 1  
5-10 
Oct4+ 1 
 
5-10 
Oct4- 4  
5-10 
Oct4- 4  
5-10 
Oct4- 4 
 
Day10 
No Sort 4  
Day10 
No Sort 4  
Day10 
No Sort 4 
Nkx2.5 3 Oct4+ 4 Tbx1 3 Oct4+ 4 Myh6 3 Oct4+ 4 
 3 Oct4- 4  3 Oct4- 4  3 Oct4- 3 
 
3 No 
Sort 4  
3 No 
Sort 4  
3 No 
Sort 4 
 4 Oct4+ 3  4 Oct4+ 4  4 Oct4+ 4 
 4 Oct4- 4  4 Oct4- 4  4 Oct4- 3 
 
4 No 
Sort 3  
4 No 
Sort 3  
4 No 
Sort 3 
 5 Oct4+ 3  5 Oct4+ 3  5 Oct4+ 3 
 5 Oct4- 3  5 Oct4- 3  5 Oct4- 3 
 
5 No 
Sort 3  
5 No 
Sort 3  
5 No 
Sort 3 
 
3-10 
Oct4+ 4  
3-10 
Oct4+ 4  
3-10 
Oct4+ 4 
 
3-10 
Oct4- 2  
3-10 
Oct4- 2  
3-10 
Oct4- 2 
 
4-10 
Oct4+ 4  
4-10 
Oct4+ 4  
4-10 
Oct4+ 4 
 
4-10 
Oct4- 4  
4-10 
Oct4- 4  
4-10 
Oct4- 4 
 
5-10 
Oct4+ 1  
5-10 
Oct4+ 2  
5-10 
Oct4+ 1 
 
5-10 
Oct4- 4  
5-10 
Oct4- 1  
5-10 
Oct4- 4 
 
Day10 
No Sort 4  
Day10 
No Sort 4  
Day10 
No Sort 4 
 
Table 2: Sample size for qPCR analysis. 
Sample counts for each population analyzed. 
 
